In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

Background and objective: We explored which clinical and biochemical variables predict
conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis …

Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune
disease, supportive evidence is perhaps circumstantial, often based on animal studies, and …

Multiple sclerosis (MS) is a chronic, progressive disorder of the central nervous system
(CNS) that affects more than two million people worldwide. Several animal models resemble …

The notion of immunological pathways playing a role in the etiology of a subset of psychotic
disorders has received increased interest in the last decades. One of the findings that has …

A better understanding of immune-mediated mechanisms in the pathogenesis of multiple
sclerosis and the contribution of environmental risk factors toward the development of …

Objectives: To estimate average annual cost per multiple sclerosis (MS) patient in the US
using published estimates from the literature. Methods: A search was performed of English …

Dimethyl fumarate (DMF) is a fumaric acid ester registered for the treatment of relapsing‐
remitting multiple sclerosis (RRMS). It induces protein succination leading to inactivation of …

Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disorder of the central
nervous system (CNS) and one of the leading causes of neurological deficits and disability …